HealthQuill Alzheimer's Disease Therapy
Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed to rope in a partner to cut costs of obtaining standard regulatory approval.
Drugs Health Pharma

Biogen abandons Alzheimer’s drug Aduhelm to focus on Leqembi

Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed.

Read More
Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio, the companies announced.
Drugs Health Pharma

Bristol Myers to acquire Karuna Therapeutics for $14 billion

HQ Team December 23, 2023: Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio,.

Read More
Japan’s Eisai Co., and US-based Biogen Inc., announced its Leqembi injection will be sold in Japan from Japan from December 20, the second country after the US.
Drugs Health Pharma

Eisai, Biogen to sell Alzheimer’s drug in Japan starting December 20 

HQ Team December 13, 2023: Japan’s Eisai Co., and US-based Biogen Inc., announced its Leqembi injection will be sold in Japan from Japan.

Read More
X